ARS Pharmaceuticals develops treatments for severe allergic reactions, notably an epinephrine nasal spray designed as a needle-free alternative to auto-injectors. Its lead product targets emergency use in anaphylaxis for patients and caregivers who may prefer or better tolerate a nasal route. The business model centers on specialty pharmaceuticals for allergy emergencies rather than broad primary-care drug portfolios.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 8 | — | -33.9 | — |
| Q2 2025 | 15.7 | — | -44.9 | — |
| Q3 2025 | 32.5 | — | -51.1 | — |
| Q4 2025 | 28.1 | — | -41.3 | — |
| Q1 2026 | 22.7 | 184.5% | -60.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Terra Innovatum Global N.V. (NKLR), Arvinas, Inc. (ARVN), Krispy Kreme, Inc. (DNUT), Cantor Equity Partners IV, Inc. (CEPF), Capital Bancorp, Inc. (CBNK), Bridgewater Bancshares, Inc. (BWB)